London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Looking at some massive trades I wonder if the mm's have been playing games - dropping the SP to trigger autosells or 'shaking the tree' to fill orders?
Yes pinto, nice to buy these at half price, I share your enthusiasm about this company!
4.8p was the low point for this century!! I need the Tardis to take me to 2023 and observe the sp at £1 (and that I was sensible enough to hang on to them!!)
At these low prices, your money's safe! With the carnage in natural resources continuing, I can see bio pharmas attracting investment.
Topped up further at 4.9p.......at least my average has dropped to 5.5p. Roll on 10p!!!
couldn't resist almost doubled my stake in here today, cannot believe the SP is so low, I think this company will address their problems and progress,growing pains? Buy on further weakness? you have a bet!
again...........either foolish or bold
Good cheap growth imv
here c5.9 - rel cheap growth & decent buying support imv... ...but could revisit much lower levels (2-3p) given limited tnw & vulnerability to rev shocks all opinion only
Yes - all very valid points. I was in here a couple of years ago and saw the meteoric rise from sub 3p to 12p (though I jumped at 9p) and have only recently bought back in on SP weakness. I think their products are certainly innovative and there's definately a market for them. They must increase the manufacturing capacity ASAP and should have no problems getting funding without a placement. I may set a STOP at 5.5p.
Their are now a number of possible concerns: the reliance on the US market; the building of a new factory, will the BOD have to go to the market to complete the funding for this? and, not least, will we ever see a return on our investment. There are obviously investors who think these concerns irrelevant, hence the odd seesaw in the price. The recent trading report was hardly inspirational, it could as well have been drafred by a Treasury official!
5.9p
50% down in a year. Maybe I was foolish to double up last month.
Who knows ? loads of buys in last few days n no change then a few sells n it goes south, gotta be sum reason for it?
Hi all, How many buys does this normally take to shift it northwards? TIA PS For anybody fron SUN listening, you can borrow my garage. :-) Best regards RRJ
GLA
Adjusted earnings before interest, tax, depreciation, and amortisation (EBITDA) for the period was projected to reach £2.85m, up from £2.8m. The firm ended the year with short term borrowings of £1.4m against bank facilities provided by HSBC of £2.0m. Graham Bowland, Chief Executive Officer, said: "I am pleased with the strong sales performance that we've achieved in the second half of the year. "There is no doubt that the manufacturing capacity constraints we experienced in the final quarter of 2012 justify the need for our proposed new facility part funded by the award of the £5.0m regional growth fund."
Surgical Innovations Group's shares tumbled Tuesday after the company said 2012 revenues were hit by manufacturing capacity constraints and delays in regulatory approvals in the final quarter. Shares fell almost 15% on the morning of the announcement as the group said it expected total revenue last year to come to £7.6m, unchanged from 2011. The designer and manufacturer of solutions for surgery said manufacturing capacity constraints its UK facility in Leeds and a delay in US regulatory approval impacted revenues towards the end of the financial year. As a result, revenues of £1.0m were not seen until January. Nevertheless, trading improved 85% to £5.6m during the last half of the year, driven by an increase in product orders. The company's SI Brand business represented 68% of overall revenues, compared to 62% in 2011. Gross margins were anticipated to have improved by three basis points to 50.3%, up from 47.3% the year earlier.
More concerned about their aim during joint armed operations abroad lol.
You don't believe that guff about "Best ally" do you? Look how they've caned BP and GSK.
Unbelievable. Long term-itis strikes again.. Did I miss something??.. beeter 2nd half,like for like sales,increased profit margin and starting this years figures up £1m to boot. Will just top up before Aprils prelims.. stuff it. Going back to bed.
Zzzzzzzzzzzzzzzzzzzzzzzzz Is it Xmas yet?
double buys to sells and showing small drop.
Can't see an import ban with their supposed best ally. If things got that bad economically in the US..I'd think we'd have worse things here to think about than the batch price of 5mm n 3mm pretzelfex's :) Strategy=pass on the cost to an already outrageously profitable U.S private health sector.